Karyopharm Therapeutics (KPTI) Receiving Somewhat Positive News Coverage, Study Shows
News stories about Karyopharm Therapeutics (NASDAQ:KPTI) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.175159934964 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Several research firms recently commented on KPTI. BidaskClub cut Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. ValuEngine cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 31st. Royal Bank Of Canada started coverage on Karyopharm Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $14.00 target price for the company. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Thursday, July 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, September 20th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $15.38.
Karyopharm Therapeutics (NASDAQ:KPTI) traded up 0.59% during trading on Monday, hitting $10.22. The stock had a trading volume of 125,604 shares. The firm’s market cap is $481.75 million. The company’s 50 day moving average is $10.97 and its 200 day moving average is $9.80. Karyopharm Therapeutics has a 52-week low of $6.27 and a 52-week high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The firm’s quarterly revenue was down 95.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.84) EPS. Equities research analysts forecast that Karyopharm Therapeutics will post ($2.62) earnings per share for the current year.
In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $11.00, for a total value of $31,702.00. Following the sale, the director now directly owns 2,882 shares of the company’s stock, valued at $31,702. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 10,695 shares of company stock worth $118,950 over the last three months. Corporate insiders own 14.71% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Karyopharm Therapeutics (KPTI) Receiving Somewhat Positive News Coverage, Study Shows” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://theolympiareport.com/2017/10/30/karyopharm-therapeutics-kpti-receiving-somewhat-positive-news-coverage-study-shows.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.